## REPORT OF THE COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS\*

CEJA Report 9-I-07

Subject: Umbilical Cord Blood Banking

Presented by: Mark A. Levine, MD, Chair

Referred to: Reference Committee on Amendments to Constitution and Bylaws

(Jane C.K. Fitch, MD, Chair)

#### BACKGROUND: UMBILICAL CORD BLOOD

Umbilical cord blood is a potential source of stem and progenitor cells, which may eventually be used to reconstitute tissue, organs, or entire systems. The first successful transplantation of umbilical cord blood occurred in 1988, with the reconstitution of a 6 year-old child's blood, bone marrow, and immune cells using his sister's cord blood. Since then, more than 6,000 unrelated-donor cord-blood transplants have been done in 150 locations worldwide. Cord blood transplants have been recommended or performed for a variety of diseases including leukemias, lymphomas, sarcomas, immune deficiencies, and some metabolic disorders. The first public cord blood bank was created at the New York Blood Center in 1991; other banks, both public and commercial, entered the field in the 1990's and early 2000's. In 2004, the US Congress allocated \$20 million to increase the stock of cord blood units in public banks.

Cord blood is collected by an obstetrician or other licensed practitioner, either before or after delivery of the placenta. "In utero" collection is performed after delivery of the newborn but before delivery of the placenta, "ex utero" after the delivery of the placenta.<sup>3</sup> In both methods, the umbilical cord is clamped at one end, a needle is inserted into the umbilical vein on the unclamped end, and the blood is allowed to flow through the needle into a collection bag. <sup>1,4</sup>

Public banks are non-profit agencies that receive cord blood by non-directed donation; the blood is stored confidentially for use by the general population. Currently the National Marrow Donor Program (NMDP) Center for Cord Blood has 45,000 units stored and registered.<sup>5</sup> Commercial, private banks, on the other hand, are for-profit entities that store blood for a fee charged to the parents of the child. The blood is then available only at the direction of the parents, for autologous transplantation or for transplant into a family member.<sup>1</sup>

Cord blood transplantation offers a number of benefits to both individuals and society. The outcomes of autologous cord blood transplantation are generally good, and the incidence of graft-

<sup>\*</sup> Reports of the Council on Ethical and Judicial Affairs are assigned to the reference committee on Constitution and Bylaws. They may be adopted, not adopted, or referred. A report may not be amended, except to clarify the meaning of the report and only with the concurrence of the Council.

<sup>© 2007</sup> American Medical Association. All Rights Reserved

versus-host disease is "10-fold lower than that seen after transplantation with HLA-matched bone 1 marrow obtained from a sibling." Public cord blood banks increase the availability of 2 3 hematopoietic stem cells, particularly for ethnic groups underrepresented in bone marrow 4 registries. Private storage of cord blood may be one reasonable option for families with a known 5 history of genetic disease that can be alleviated by cord blood transplantation, or when a sibling or 6 other family member needs a stem cell transplant.<sup>4</sup>

7 8

#### ETHICAL ISSUES IN UMBILICAL CORD BLOOD COLLECTION AND BANKING

9 10

## Informed Consent

11 12

13

14

15

16

A number of ethical considerations surrounding the collection and storage of umbilical cord blood deserve careful attention. The first, and most basic, is the issue of informed consent. Previously, umbilical cord blood was considered waste, and thereby was the property of the hospital to be used as the institution saw fit (without the knowledge or consent of the mother).<sup>6</sup> In recent years, the necessity to inform patients if their cord blood is to be collected has been recognized. but timing of consent can be challenging.

17 18 19

20

21

Most practitioners agree that ideally, consent should be obtained before the onset of labor; however, women often arrive at the hospital already in labor, with no prior knowledge of the possibility of cord blood donation. This is a stressful time for parents, so obtaining a genuine informed consent can be difficult.

22 23 24

25

26

27

A variety of consent procedures are currently used. Public banks usually seek consent during the prenatal care period, but may ask for consent when a woman enters the hospital during labor or may collect the cord blood without consent, obtaining consent after the collection is performed.<sup>7</sup> After the onset of labor would not be an appropriate time for a physician to bring up private banking.

28 29 30

31

32

33 34 Private banks usually secure written consent during the prenatal care period. Consent is sometimes in the form of an online agreement to which a prospective customer must agree before obtaining further services from the private facility. Such agreements are contractual in nature, and are a poor substitute for in-person interaction with a health care professional to discuss the risks, benefits and alternatives to the collection and storage of cord blood, as generally described in Opinion E-8.08, "Informed Consent" in the AMA's Code of Medical Ethics.9

35 36 37

38

39

40

41

42

43

The informed consent process for umbilical cord blood banking should include specific disclosure of the collection process, the details of what will happen to the sample once it is collected, and the spectrum of banking options that are available. When making a decision of whether or not to have the cord blood collected and stored, a woman should understand that, due to complications during childbirth, it may be in the best interest of the mother and child to forgo collection, and moreover that sometimes not enough blood can be saved to constitute a usable sample. Furthermore, a woman also should understand the need for additional testing for a variety of diseases and the potential implications of the tests results, including the possibility that the cord blood sample will

44 not be stored if the sample does not meet certain criteria. <sup>6,10</sup> 45

- 1 The informed consent process for donation to a public bank should include disclosure that the
- 2 sample will not be available for retrieval and use by family in the future, because donations to
- 3 public storage facilities may be used for transplantation to other patients or other testing or research
- 4 purposes. Additional disclosures should explain that the use of cord blood for clinical
- 5 transplantation is currently experimental and some of its clinical usage falls under the heading of an
- 6 investigational new drug (IND) by the Food and Drug Administration; thus, some units donated to
- 7 public banks may be used in experimental protocols.
- 8 The consent process for private banking should provide information regarding the utility of
- 9 banking cord blood and the likelihood of future use. Though research on stem cells found in cord
- blood promotes speculation about a variety of future uses, the most recent findings suggest that
- there is only a 1 in 20,000 chance that a not-at-risk child would develop a condition which would
- necessitate the use of his or her own cord blood. 11 Patients should also be informed that there exist
  - uncertainties whether long-term storage affects the future utility of cord blood. 12
- 13 14

## Claims Related to Medical Benefits

15 16

- 17 Sound informed consent is based on complete and accurate information presented to a patient.
- 18 Therefore, disclosure of risks, benefits, advantages, and disadvantages of banking blood in public
- versus private banks is critical. The utility of autologous cord blood transplantation is a key selling point used by private banks to aggressively market their services; yet, such blood has only limited
  - point used by private banks to aggressively market their services; yet, such blood has only limited
- value, according to current evidence.

22

- No current evidence suggests that cord blood can be used to treat illnesses resulting from injury or aging. Furthermore, autologous transplantation is not the procedure of choice for some diseases for
- 25 which commercial banks recommend cord blood as a treatment option. According to the American
- Academy of Pediatrics Work Group on Cord Blood Banking, the overall outcomes of autologous
- transplantation in cases of leukemia, lymphomas, and neuroblastomas are no better than those of
- 28 allogeneic transplantation. In fact, most forms of leukemia can be treated by conventional
- 29 chemotherapy, making autologous transplantation unnecessary. Moreover, some private banks
- claim storage of cord blood might one day save a child from leukemia, but leukemic or pre-
- 31 leukemic cells have been found in autologous cord blood samples from children presenting with
- 32 leukemia between the ages of 1 and 11, making samples unsafe to the original donor or to any other
- 33 potential recipient.<sup>1</sup>

34 35

- Commercial cord blood banks recruit customers by making general claims about the future health of their children, for example, declaring that "banking your baby's cord blood today could make a
- of their children, for example, declaring that "banking your baby's cord blood today could make major impact on your family in years to come" or "Collecting Cord Blood offers a once-in-a-
- 38 lifetime opportunity to obtain stem cells."<sup>14</sup> The probability of actually using this stored cord
- 39 blood, however, is negligible: estimates range from 1:1000 to 1:200,000, and no empirical evidence
  - favors widespread usage of autologous transplantation in the future.<sup>2, 15</sup>

40 41

- The number of hematopoietic stem cells transplanted may be important to the outcome of the
- 43 procedure. Consequently, parents may have paid for cord blood units to be stored which might be
- 44 insufficient to meet the needs of their children, particularly as those children mature and reach
- adulthood when the number of cells needed for treatment is greater than the quantity needed to

treat newborns.<sup>1,2</sup> Techniques are currently being developed to increase volume of cord blood in order to make samples harvested from newborns usable for adults, but these processes are still experimental and it may be years before they are refined enough for clinical use.<sup>3</sup>

3 4 5

1

2

## Conflicts of Interest

6 7

8

9 10

11

12

An additional concern is physicians' financial ties to cord blood banks. Opinion E-8.03, "Conflicts of Interest: Guidelines" states "Under no circumstances may physicians place their own financial interest above that of their patients."<sup>15</sup> In cord blood banking, conflicts of interest may arise in a variety of circumstances. For example, physicians potentially can benefit from research with financial implications. 11 Full disclosure of and consent for research intentions as well as any potential commercial use that can lead to physicians' financial gains must be made to a potential donor as detailed in Opinion E-2.08, "Commercial Use of Human Tissue." <sup>16</sup>

13 14 15

16

17

18 19 Physicians may have relationships with private cord blood banks that benefit then financially if they convince their patients to store cord blood at the given facility. Private banks charge an initial storage fee of between \$1,000 and \$1,500, and subsequent yearly fees are generally around \$100. 1,18,19 As stated in Opinion E-6.02, "Fee Splitting," accepting payment from a source for referring parents to that source constitutes fee splitting and would violate the requirement to deal honestly with patients and colleagues.<sup>20</sup>

20 21 22

23

Concerns about the efficacy of autologous cord blood transplantation have led some to question the need for private cord blood banks. In most cases it is inappropriate to recommend storage of cord blood at a private facility.

24 25 26

## Other Considerations

27 28

29

30

31

The timing of umbilical cord clamping is also important to consider. Collection procedures must not interfere with standard delivery practices and the safety of a newborn or the mother. It is unlikely that health care professionals will endanger the lives of newborns for the sake of cord blood collection, but the risk remains. Still, parents might be paying for and/or accepting a practice that could endanger the lives of their newborn children.<sup>2</sup>

32 33 34

35

36 37

38

39 40

41

Cord blood that is privately banked may engender questions of ownership. Though the parents of the child will likely be paying the fees for storage, the question of whether the blood belongs to the parent or child may be raised. Some private banks require parents to agree to general "Terms and Conditions" which specify exactly when a child will receive ownership claims to his or her cord blood sample, often at age 25, and what will happen to a sample if payment for storage is not made, (the company "will retain all rights to the cord blood unit"). In the absence of clear contractual terms, there is uncertainty as to what should be done with a cord blood sample if a family stops paying a private bank's storage fee.<sup>3</sup> It has been suggested that abandoned blood could be used for research purposes, as long as the donor's identity is kept confidential, but that it should be

42 considered unethical for the blood to be sold for the rapeutic use. 11 43

Several ethical questions may arise involving the protection of the privacy of the donor mother and child. Cord blood donations are tested for a variety of infectious diseases and genetic abnormalities, and the question of who may be informed of the results of these tests (i.e., mother, father, and child) may arise. A separate issue for public banks is whether or not a long-term link between donor and donation should exist.<sup>3</sup> Some concerns related to the privacy of the donor arise when considering the safety of a sample for any given recipient. If identifying information is not kept which can link a sample to its donor, then in the event a medical condition (e.g., leukemia) appears later in the donor-child's life, the cord blood which would be unsafe could go unidentified and remain in a public pool. Additionally, keeping a link to the donor could be beneficial to any recipient if additional blood cells are needed; however, this link also poses a risk of violating

#### CONCLUSION

Treatments using umbilical cord blood stem cells have been successful and point to the possibility of a great potential for treating a wider variety of people and diseases with cord blood in the future. Thus, at this time it is appropriate to collect and bank this resource in order to make the supply as diverse and as available as possible to the greatest number of patients for experimental therapy and to researchers for continued exploration. Ethical concerns present themselves at various points in the process of obtaining cord blood samples and careful consideration must be given to fully informing potential donors of the full spectrum of options and their respective advantages as well as disadvantages.

#### RECOMMENDATION

The Council on Ethical and Judicial Affairs recommends that Opinion E-2.165, "Fetal Umbilical Cord Blood," be replaced with the following and the remainder of this report be filed.

## E-2.165 Fetal Umbilical Cord Blood

confidentiality of both the mother and child.

Umbilical cord blood stem cells are useful for some therapeutic purposes. Physicians providing obstetrical care should be prepared to inform pregnant women of the various options regarding cord blood donation or storage and the potential uses of donated samples. Collection procedures must not interfere with standard delivery practices and the safety of a newborn or the mother.

Informed consent for the collection of umbilical cord blood stem cells should be obtained, when feasible, before the onset of labor. Physicians' ties to public and private cord blood banks must be disclosed during the informed consent process. Physicians shall not accept financial or other inducements for providing samples to cord blood banks.

The utility of umbilical cord blood stem cells is greater when the donation is to a public rather than private bank. Therefore, physicians should encourage women who wish to donate cord blood to donate to a public bank if one is available. Doing so will result in greater availability of stem cells to patients from minority populations.

1	
2	Private banking should be considered in the unusual circumstance when there exists a
3	family predisposition to a condition in which umbilical cord stem cells are therapeutically
4	indicated. However, because of its cost, limited likelihood of use, and inaccessibility to
5	others, private banking should not be recommended to low-risk families.
6	
7	Because safety and effectiveness of various methods of cord blood collection and use
8	continue to evolve, physicians should monitor the results of ongoing research.
9	
10	(New HOD/CEJA Policy)

Fiscal Note: Staff cost estimated at less than \$500 to implement.

#### References

<sup>1</sup>Kurtzberg J, Lyerly, Drapkin A, Sugarman J. Untying the Gordian knot: policies, practices, and ethical issues related to banking of umbilical cord blood. *J Clin Invest.* 2005;115(10):2592-2597.

<sup>2</sup>Work Group on Cord Blood Banking. Cord Blood Banking for Potential Future Transplantation: Subject Review. *Pediatrics*. 1999;104(1):116-118.

<sup>3</sup>Beckman A, Lubin Bertram H, Greene MF. Collection and storage of umbilical cord blood for hematopoietic cell transplantation. *UpToDate*. http://www.patients.uptodate.com/topic.asp?file=hcell\_tr/10338. Accessed December 10, 2006.

<sup>4</sup>KidsHealth for Parents. Banking Your Newborn's Cord Blood. Nemours Foundation.

http://kidshealth.org/parent/pregnancy\_newborn/pregnancy/cord\_blood.html. Accessed December 10, 2006.

<sup>5</sup>Cord Blood Transplantation & NMDP. *National Marrow Donor Program*.

http://www.marrow.org/NMDP/cord blood idx.html. Accessed December 10, 2006.

<sup>6</sup>Gluckman, E; for Eurocord Netcord Organisation. Ethical and legal aspects of placental/cord blood banking and transplant. *Hematol J.* 2000;1(1):67-69.

<sup>7</sup>Meyer EA, Hanna K, Gebbie K, eds. Cord Blood: Establishing a National Hematopoietic Stem Cell Bank Program. Washington, DC: The National Academies Press; 2005.

http://newton.nap.edu/books/0309095867/html/R1.html. Accessed December 10, 2006.

<sup>8</sup>Viacord: Enrollment Information and Enrollment Agreement. *Viacord*. Available at:

http://www.viacord.com/enroll.htm. Accessed December 10, 2006.

<sup>9</sup>American Medical Association. Opinion E-8.08 Informed Consent. *AMA Code of Medical Ethics*. Chicago, IL: American Medical Association; 2006. http://www.ama-assn.org/ama/pub/category/8488.html. Accessed Sept 3, 2007.

<sup>10</sup>Sugarman J, Kaalund V, Kodish E, et al. Ethical Issues in Umbilical Cord Banking. *JAMA*. 1997;278(11):938-943.

<sup>11</sup>Annas GJ. Waste and Longing- The Legal Status of Placental-Blood Banking. *N Engl J Med.* 1999;340(19):1521-1524.

<sup>12</sup>ACOG committee opinion. Routine storage of umbilical cord blood for potential future transplantation. Number 183, April 1997. Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. *Int J Gynaecol Obste*. 1997;58(2):257-259.

<sup>13</sup>Why Cord Blood? *Viacord*. http://www.viacord.com/banking-why-cord-blood.htm. Accessed November 29, 2006.

<sup>14</sup>Alphacord: Learn About Cord Blood. http://www.alphacord.com/Learn.aspx Accessed December 11, 2006.

<sup>15</sup> Fisk NM, Roberts IAG, Markwald R, Mironov V. Can Routine Commercial Cord Blood Banking Be Scientifically and Ethically Justified. *PLoS Medicine*. 2005;2(2):e44 doi:10.1371/journal.pmed.0020044

<sup>16</sup>American Medical Association. Opinion E-8.03 Conflicts of Interest: Guidelines. *AMA Code of Medical Ethics*. Chicago, IL: American Medical Association; 2006. http://www.ama-assn.org/ama/pub/category/8469.html. Accessed Sept 3, 2007.

<sup>17</sup>American Medical Association. Opinion E-2.08 Commercial Use of Human Tissue. *AMA Code of Medical Ethics*. Chicago, IL: American Medical Association; 2006. http://www.ama-assn.org/ama/pub/category/8427.html. Accessed Sept 3, 2007.

<sup>18</sup>AlphaCord. http://www.alphacord.com/free\_info\_packet.asp. Accessed December 10, 2006.

<sup>19</sup> The Genesis Bank. http://www.thegenesisbank.com. Accessed December 10, 2006.

<sup>20</sup>American Medical Association. Opinion E-6.02 Fee Splitting. *AMA Code of Medical Ethics*. Chicago, IL: American Medical Association; 2006. http://www.ama-assn.org/ama/pub/category/8365.html. Accessed Sept 3, 2007.